Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 3/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923027 | 0.81 | NOS1 (0.37) | NOS1CTSAAPLNR | |
| SCHEMBL2600726 | 0.77 | NOS1 (0.44) | NOS1TLR8TLR7CTSAAPLNR | |
| SCHEMBL2483086 | 0.74 | ALDH1A1 (0.49) | TLR8TLR7 | |
| SCHEMBL13104307 | 0.74 | RXFP1 (0.47) | — | |
| SCHEMBL23869812 | 0.73 | NOS1 (0.41) | NOS1CTSAAPLNR | |
| SCHEMBL20738686 | 0.73 | NOS1 (0.41) | NOS1CTSAAPLNR | |
| SCHEMBL3248176 | 0.73 | NOS1 (0.46) | NOS1CTSAAPLNR | |
| SCHEMBL12179230 | 0.73 | NOS1 (0.41) | NOS1CTSAAPLNR | |
| SCHEMBL6010207 | 0.73 | NOS1 (0.41) | NOS1CTSAAPLNR | |
| SCHEMBL30209038 | 0.73 | NOS1 (0.46) | NOS1CTSAAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | NOS1 335/4885TLR8 40/4885TLR7 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.